Clinical Trials Browser

Phase 1/2 × NETWORK × bosutinib × Clear all

NCT04258943 2025-09-18

Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia

Phase 1/2 Active not recruiting

60 enrolled 1 FDA

MyeloidOther hematologic neoplasm

Blast Crisis, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase